EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.

Ann Rheum Dis.

Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M

doi: 10.1136/

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Ann Rheum Dis.

Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T

doi: 10.1136/annrheumdis-2020-217139.

EULAR ^® 2019

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Rheumatic and Musculoskeletal Diseases

Yusof et al. 2019. Predicting severe infection in repeat cycles of rituximab and effects of hypogammaglobulinemia for the treatment of rheumatic and musculoskeletal diseases. Oral presentation presented at: EULAR 2019 Congress; 12–15 June 2019; Madrid, Spain.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Ann Rheum Dis.

Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, Combe B, Galli M, Gossec L, Iagnocco A, Isaacs JD, Mariette X, McInnes I, Mueller-Ladner U, Openshaw P, Smolen JS, Stamm TA, Wiek D, Schulze-Koops H

doi: 10.1136/annrheumdis-2020-217877.

Rheumatoid Arthritis

Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries

Ann Rheum Dis

Dejaco C, Alunno A, Bijlsma JW, Boonen A, Combe B, Finckh A, Machado PM, Padjen I, Sivera F, Stamm TA, Buttgereit F

doi: 10.1136/annrheumdis-2020-218697

Immunotherapy

2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

Ann Rheum Dis

Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Giacomelli R, Hermine O, Isaacs JD, Koné-Paut I, Magro-Checa C, McInnes IB, Meroni PL, Quartuccio L, Ramanan AV, Ramos-Casals M, Rodríguez Carrio J, Schulze-Koops H, Stamm TA, Tas SW, Terrier B, McGonagle DG, Mariette X

doi: 10.1136/annrheumdis-2021-221366

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

2019 EULAR points to consider for the assessment of competences in rheumatology specialty training

Ann Rheum Dis.

Sivera F, Alunno A, Najm A, Avcin T, Baraliakos X, Bijlsma JW, Badreh S, Burmester G, Cikes N, Da Silva JA, Damjanov N, Dougados M, Dudler J, Edwards CJ, Iagnocco A, Lioté F, Nikiphorou E, van Onna M, Stones SR, Vassilopoulos D, Haines C, Ramiro S

doi: 10.1136/annrheumdis-2020-218015.

Further Publications Rheumatology

EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis

Ann Rheum Dis

Mankia K, Siddle HJ, Kerschbaumer A, Alpizar Rodriguez D, Catrina AI, Canete JD, Cope AP, Daien CI, Deane KD, El Gabalawy H, Finckh A, Holers VM, Koloumas M, Ometto F, Raza K, Zabalan C, van der Helm-van Mil A, van Schaardenburg D, Aletaha D, Emery P

doi: 10.1136/annrheumdis-2021-220884

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases

Arthritis Rheumatol.

Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'Anci KE

doi: 10.1002/art.41191.

Related content

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Rheumatic and Musculoskeletal Diseases

EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries

2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

2019 EULAR points to consider for the assessment of competences in rheumatology specialty training

EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis

2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases